Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Preliminary Phase 1 results for oral GLP-1 receptor agonist BMF-650 showed mean Day-29 weight loss of 1.5%–3.2% in outpatient cohorts versus 0.1% for placebo, and 6.1% in a confined cohort after rapid titration. Reported gastrointestinal events were mild or moderate.
Biomea Fusion reported Phase 1 results for oral GLP-1 drug candidate BMF-650, showing early signs of weight loss activity. Outcomes pointed to consistent short-term weight reduction versus placebo, without detailing specific efficacy measurements. Tolerability looked manageable, with no severe safety events reported in